Doxofylline (Standard)

• UNSPSC Description:

  Doxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm[1][2][3].

• Target Antigen:

  Adenosine Receptor; Phosphodiesterase (PDE); Reactive Oxygen Species

• Type:

  Reference Standards

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/doxofylline-standard.html

• Smiles:

  O=C(N1C)N(C)C2=C(N(CC3OCCO3)C=N2)C1=O

• Molecular Weight:

  266.25

• References & Citations:

  [1]Jiao P, et al. The protective effect of doxofylline against lipopolysaccharides (LPS)-induced activation of NLRP3 inflammasome is mediated by SIRT1 in human pulmonary bronchial epithelial cells. Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):687-694. |[2]Riffo-Vasquez Y, et al. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm Pharmacol Ther. 2014 Apr;27(2):170-8.|[3]Shukla D, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009 Oct;10(14):2343-56.

• Shipping Conditions:

  Room temperature

• CAS Number:

  69975-86-6